Emergent Biosolutions Inc
NYSE:EBS
| Market Cap (Intraday) | 116.80M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | 0.56 |
| 10-Day MA | $2.06 |
| 50-Day MA | $2.39 |
| 200-Day MA | $3.26 |
Emergent Biosolutions Inc Stock, NYSE:EBS
300 Professional Drive, Suite 400, Gaithersburg, Maryland 20879
United States of America
Phone: +1.240.631.3200
Number of Employees: 1600
Description
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.